hydrazine has been researched along with Agnogenic Myeloid Metaplasia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Akyürek, N; Aydın Kaynar, L; Bostankolu Değirmenci, B; Dikyar, A; Özkurt, ZN; Uyar Göçün, P; Yegin, ZA | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kadia, T; Masarova, L; Matthews, J; Naqvi, K; Ravandi, F; Sasaki, K; Shoukier, M; Verstovsek, S | 1 |
| Balduini, CL; Pecci, A; Rodeghiero, F | 1 |
| Bailey, CK; Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D | 1 |
| Cenci, T; Foà, R; Giona, F; Larocca, LM; Leone, G; Martini, M; Teofili, L; Torti, L | 1 |
| Boiocchi, L; Bussel, JB; Feng, X; Geyer, JT; Ghanima, W; Gudbrandsdottir, S; Hasselbalch, HC; Junker, P; Orazi, A | 1 |
1 review(s) available for hydrazine and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Topics: Benzoates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Association Studies; Genetic Heterogeneity; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Hydrazines; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Thrombocytopenia; Thrombophilia; Thrombopoiesis; Thrombopoietin | 2018 |
1 trial(s) available for hydrazine and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Topics: Adult; Benzoates; Bone Marrow; Bone Marrow Examination; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Reticulin | 2015 |
4 other study(ies) available for hydrazine and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia.
Topics: Benzoates; Female; Fibrosis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Middle Aged; Primary Myelofibrosis; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Topics: Benzoates; Humans; Hydrazines; Mutation; Primary Myelofibrosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombocytosis; Thrombopoietin; Transcriptional Activation | 2010 |
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Topics: Adult; Benzoates; Bone Marrow; Combined Modality Therapy; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Peptide Fragments; Primary Myelofibrosis; Procollagen; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Reticulin; Splenectomy; Thrombopoietin | 2011 |